Drugs to Facilitate Smoking Cessation
A growing number of pharmacologic options, including nicotine-replacement therapies, are available to help people quit smoking cigarettes.
Antipsychotics and Mortality in Parkinson Disease
In a recent study of patients with Parkinson disease, treatment with an antipsychotic was associated with a twofold increase in the risk of death.
Increased Energy Output from Physical Activity Linked to Larger Gray Matter Volumes in Elderly; Psilocybin Shows Benefit for Treatment-Resistant Depression in Small Open-Label Trial
Anti-inflammatory Agents as Adjuncts against Bipolar Depression
In a systematic review of clinical trials employing adjunctive anti-inflammatory agents to treat bipolar depression, investigators found a statistically significant antidepressant benefit.
A Message from Alan J. Gelenberg, M.D.
When I first started writing BTP in the 1970s, it was to bridge the gap between new knowledge in our field and its application to patient care. Over the decades since, the need for this bridge has become even greater. Neuroscience rockets forward. Psychiatrists and other clinicians have a broader array of treatments for patients with mental disorders than we even dreamed of back then. But we have less time to spend with patients and less time to keep up with developments that affect treatment decisions. Our medications, and those prescribed by colleagues in other specialties, are more varied, complex, and prone to interactions. What were formerly crisp boundaries between major psychopharmacologic categories are now murky.
This makes the modern practice of psychiatry challenging—but also fun and promising. With the expanding armamentarium of treatment options comes enhanced ability to alleviate suffering. The mission of BTP remains constant, even while the field grows. We are still here to bridge the gap, to make science applicable and relevant, and to help you in your day-to-day work relieve distress and improve function in patients' lives.